SCCA Clinical Studies: Phase I Program
RO5429083 Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Investigator: Andrew L. Coveler, MD; Conditions: Neoplasms; Status: Recruiting; Study ID: NCT01358903
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma; Status: Recruiting; Study ID: NCT00729664
A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)
Investigator: Scott S. Tykodi, MD, PhD ; Conditions: Advanced/ Metastatic Renal Cell Cancer; Status: Closed; Study ID: NCT00715182
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT00953758
An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
Investigator: Dr. Ajay Gopal; Conditions: Hodgkin's Lymphoma, , Large-Cell Anaplastic Lymphoma, Non-Hodgkin's Lymphoma; Status: Recruiting; Study ID: NCT01026415
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Not Recruiting; Study ID: NCT01063816
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer
Investigator: Eve Rodler, MD; Conditions: Advanced Breast Cancer; Status: Recruiting; Study ID: NCT01104259
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma
Investigator: Dr John Thompson; Conditions: Renal Cell Carcinoma; Status: Recruiting; Study ID: NCT01114230
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Investigator: Barbara A. Goff, MD; Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma; Status: Recruiting; Study ID: NCT01091428
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)
Investigator: Laura Chow, MD; Conditions: Tumors Characterized by Genetic Abnormalities of ALK; Status: Recruiting; Study ID: NCT01283516
A Phase 1b/2 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Investigator: Ajay K. Gopal, MD; Conditions: Relapsed Indolent B-cell Lymphoma; Status: Recruiting; Study ID: NCT01317901
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Investigator: Ajay K. Gopal, MD; Conditions: Non-Hodgkin's Lymphoma (NHL); Status: Recruiting; Study ID: NCT01307267
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01300247
Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma; Status: Recruiting; Study ID: NCT01399840
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine (Gemzar) Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer
Investigator: Sunil Hingorani, MD, PhD; Conditions: Pancreatic Cancer; Status: Recruiting; Study ID: NCT01453153
An Open-Label, Phase 1 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory CD22-Positive Acute Lymphocytic Leukemia
Investigator: Stephen H. Petersdorf, MD; Conditions: Acute Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01363297
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Investigator: Shailender Bhatia, M.D.; Conditions: Melanoma; Status: Recruiting; Study ID: NCT01489059